Previously, the potent aromatase inactivator (= suicide inhibitor) 4-OHA was developed by Ciba and Novartis, respectively, as intramuscular depot injection preparation (Lentaron®Depot) for treatment of the postmenopausal patients with advanced breast cancer. This evidence concerns the gene CYP19A1 and breast carcinoma.